What was the primary objective of analyzing tumor-infiltrating lymphocytes (TILs) in the APHINITY trial?
To identify biomarkers that can distinguish patients who benefit most from dual versus single HER2 blockade
To evaluate whether TILs predict resistance to all HER2-targeted therapies
To determine which HER2-targeted agent is more effective as monotherapy